The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 105.00
Bid: 102.00
Ask: 108.00
Change: 0.00 (0.00%)
Spread: 6.00 (5.882%)
Open: 104.00
High: 0.00
Low: 0.00
Prev. Close: 105.00
IGP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Amendments to LTIP

21 Aug 2012 07:00

RNS Number : 3943K
Intercede Group PLC
21 August 2012
 

21 August 2012

Intercede Group plc

("Intercede" or "the Company"))

 

Changes to Long Term Incentive Plan (LTIP)

 

Intercede is pleased to announce that, following consultation with the Company's major shareholders, the Remuneration Committee has approved certain changes to the performance conditions attached to awards made under the Company's LTIP on 16 August 2011. The changes are a result of Richard Parris, the Company's Chairman & Chief Executive, communicating to the Remuneration Committee that he would not exercise options until the price per ordinary share exceeded 200p.

 

In considering this communication, the Remuneration Committee noted that Intercede's recently announced strategy of accelerated investment in technology development and the expansion of its US footprint and capabilities was not consistent with an EPS performance target under the LTIP. The Remuneration Committee consider, having taken appropriate advice, that the change in strategy represents an event under the terms of the LTIP that allows a change to performance targets to be made.

 

Consequently the Remuneration Committee has removed the three year EPS performance target from the LTIP awards made in August 2011 and replaced it with a share price target of 200p per ordinary share as well as extending the vesting period to seven years from the date of the original award. In order to exercise the option, an average share price of 200p per ordinary share must be achieved over 30 consecutive dealing days during the period between three years and seven years from the date of the original award.

 

In addition, participants have agreed to the insertion of a further performance condition. In the event of a recommended offer for the Company at any price below 125p per ordinary share, the option will only be exercisable over such number of shares that are equivalent in value to the difference between 56p (being the mid-market share price at the time of the original grant of 57p less the 1p exercise price) and the offer price. This also means that the option would not be exercisable at all at a recommended offer price of less than 57p. At any price above 125p, or in the event of an offer that is not recommended by the Board, the option vests in full.

 

All other terms and conditions of the LTIP remain unchanged.

 

Royston Hoggarth, the Chairman of the Remuneration Committee said: "Intercede is a global software company that needs to invest to increase its market penetration and long term valuation. The Remuneration Committee consider an overall share price target more appropriately aligns the interests of the beneficiaries of the LTIP and shareholders than a short or medium term EPS performance target. The willingness by Richard to communicate a share price target that is over three times higher than the price today, and the agreement by participants to the takeover condition, demonstrates their confidence and belief in the business."

 

 

 

 

 

 

ENQUIRIES

 

Intercede Group plc

Tel. +44 (0)1455 558111

Richard Parris, Chairman & Chief Executive

Andrew Walker, Finance Director

FinnCap

Tel. + 44 (0)20 7220 0500

Stuart Andrew/Rose Herbert, Corporate Finance

Joanna Weaving, Corporate Broking

Pelham Bell Pottinger

Tel. +44 (0)20 7861 3112

Archie Berens

 

About Intercede

Intercede® is a security software provider whose MyID® identity management platform enables global organisations and governments to create trusted digital identities for employees and citizens on secure devices such as smartcards, smartphones and tablets. MyID enables the protection of IP, assets, and digital content, delivering trusted digital identities as the cornerstone of cyber security strategies for government, defence, financial services and other industries.

The Company operates in global markets (including the US, Europe and Middle East) and works with large international partners including BT, Gemalto, HP, Microsoft, Oberthur, SafeNet, Symantec and Thales to deliver flexible digital identity solutions that are interoperable with other existing technologies and which are tailored to customer needs.

Corporations such as Boeing, Booz Allen Hamilton and Lockheed Martin,and governments including the USA, UK and Kuwait, trust Intercede's deep expertise to deliver effective solutions. The company's technology achievements reflect an investment of 300 plus man years of development, exemplary speed of deployment and adherence to international standards including FIPS 201, where MyID was the first electronic personalization product to obtain GSAapproval. This trust is reflected in Intercede's rate of repeat business with its customers, which typically runs at 70-80% of annual revenues.

Intercede has been developing ID management systems since 1992 and MyID is currently deployed by end customers located in 24 countries. The company is headquartered in the UK, listed on the London Stock Exchange AIM: IGP and ISO 9001 and TickIT certified.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCZMGZRDGLGZZM
Date   Source Headline
14th Apr 20207:00 amRNSDirector/PDMR Shareholding
7th Apr 20207:00 amRNSTrading Update
3rd Apr 20205:07 pmRNSShare Incentive Plan
31st Mar 20207:00 amRNSReceipt of $4.6m Order
28th Feb 20207:00 amRNSShare Incentive Plan
26th Feb 20209:50 amRNSShare Incentive Plan
25th Feb 20207:00 amRNSShare Incentive Plan
12th Feb 202011:22 amRNSShare Award
25th Nov 20197:00 amRNSHalf-year Report
7th Oct 20197:00 amRNSTrading Update
30th Sep 20197:00 amRNSDirector/PDMR Shareholding
18th Sep 20196:30 pmRNSResult of AGM
16th Sep 20193:56 pmRNSPosting of Annual Report & Notice of AGM
17th Jun 20197:00 amRNSAppointment of Non-Executive Director
5th Jun 20197:00 amRNSFinal Results
8th Apr 20197:00 amRNSSale of Property
2nd Apr 20197:00 amRNSTrading Update
28th Feb 20197:00 amRNSNew Contract Win
4th Feb 20193:19 pmRNSHolding(s) in Company
17th Dec 201810:19 amRNSBoard Change
26th Nov 20187:00 amRNSHalf-year Report
22nd Oct 20187:00 amRNSGrant of Options
4th Oct 20187:00 amRNSTrading Statement
20th Sep 20187:00 amRNSResult of AGM
4th Sep 20187:00 amRNSDirector/PDMR Shareholding
10th Aug 20187:00 amRNSDirector/PDMR Shareholding
31st Jul 20187:00 amRNSDirector/PDMR Shareholding
10th Jul 20188:00 amRNSDirector/PDMR Shareholding
29th Jun 20184:59 pmRNSPDMR Shareholding
7th Jun 20187:00 amRNSFinal Results
26th Apr 20182:10 pmRNSPDMR Change
25th Apr 20187:00 amRNSDirector/PDMR Shareholding
20th Apr 201812:15 pmRNSPDMR Change
11th Apr 201811:36 amRNSHolding(s) in Company
11th Apr 20187:00 amRNSAppointment of Chief Executive
4th Apr 20187:00 amRNSReceipt of $4.0m Order/Trading Update
29th Mar 20187:00 amRNSDirectorate Change
9th Mar 20187:00 amRNSNew Contract Award
13th Feb 20187:00 amRNSNew Contract Award
4th Dec 20177:00 amRNSContract
30th Nov 20177:00 amRNSNew Contract Award
27th Nov 20177:00 amRNSHalf-year Report
6th Nov 20171:58 pmRNSTrading Update
26th Oct 20177:00 amRNSShare Award
5th Oct 20177:00 amRNSTrading Statement
13th Sep 20173:30 pmRNSResult of AGM
13th Sep 20177:00 amRNSDirectorate Change
25th Aug 20177:00 amRNSIssue of Convertible Loan Notes
1st Aug 20179:07 amRNSTotal Voting Rights
27th Jul 20177:00 amRNSShare Incentive Plan & Issue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.